MSK Research Roundup at ASCO 2026: Breakthrough Findings for Liposarcoma and Liver, Non‑Small Cell Lung, Prostate, and Blood Cancers
The targeted therapy abemaciclib significantly delayed time to tumor regrowth in patients with recurrent or metastatic dedifferentiated liposarcoma treated at Memorial Sloan‑Kettering Cancer Center.
In a phase‑3 multicenter SARC041 trial, the targeted therapy abemaciclib significantly delayed time to tumor regrowth in patients with recurrent or metastatic dedifferentiated liposarcoma (DDLPS), extending median progression‑free survival to 9.7 months versus 1.5 months with placebo and reducing tumor size in 1 in 10 patients. The trial was presented as an ASCO 2026 late‑breaking abstract.
DDLPS is a rare, aggressive sarcoma with limited treatment options; demonstrating a drug that improves progression‑free survival and induces tumour shrinkage offers a new therapeutic strategy that could become standard of care.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT